Cancer Research Audrey Hepburn Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donato, N. J.
Right arrow Articles by Talpaz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donato, N. J.
Right arrow Articles by Talpaz, M.
[Cancer Research 64, 672-677, January 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Nicholas J. Donato1, Ji Y. Wu1, Jonathan Stapley1, Hui Lin2, Ralph Arlinghaus2, Bharat Aggarwal1, Shishir Shishodin1, Maher Albitar3, Kimberly Hayes4, Hagop Kantarjian5 and Moshe Talpaz1

1 Departments of Bioimmunotherapy,
2 Molecular Pathology,
3 Hematopathology,
4 Cytogenetics, and
5 Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, Texas

Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.




This article has been cited by other articles:


Home page
 BloodHome page
R. J. Garg, H. Kantarjian, S. O'Brien, A. Quintas-Cardama, S. Faderl, Z. Estrov, and J. Cortes
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Blood, November 12, 2009; 114(20): 4361 - 4368.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. S. Khorashad, S. Wagner, L. Greener, D. Marin, A. Reid, D. Milojkovic, H. Patel, S. Willimott, K. Rezvani, G. Gerrard, et al.
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
Haematologica, June 1, 2009; 94(6): 861 - 864.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
S.-F. Wong
Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia
Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 17 - 27.
[Abstract] [PDF]

Home page
 BloodHome page
A. Quintas-Cardama and J. Cortes
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Blood, February 19, 2009; 113(8): 1619 - 1630.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
Blood, December 15, 2008; 112(13): 4839 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. Dai, M. Pfister, A. Blackwood-Chirchir, and A. Roy
Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia
J. Clin. Pharmacol., November 1, 2008; 48(11): 1254 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Wu, F. Meng, L.-Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, et al.
Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
J Natl Cancer Inst, July 2, 2008; 100(13): 926 - 939.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist, April 1, 2008; 13(4): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Wu, F. Meng, H. Lu, L. Kong, W. Bornmann, Z. Peng, M. Talpaz, and N. J. Donato
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Blood, April 1, 2008; 111(7): 3821 - 3829.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Konig, T. L. Holyoake, and R. Bhatia
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
Blood, February 15, 2008; 111(4): 2329 - 2338.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
M. W.N. Deininger
Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells
ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Cortes, E. Jabbour, H. Kantarjian, C. C. Yin, J. Shan, S. O'Brien, G. Garcia-Manero, F. Giles, M. Breeden, N. Reeves, et al.
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Blood, December 1, 2007; 110(12): 4005 - 4011.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. M. Lee, J. H. Bae, M. J. Kim, H. S. Lee, M. K. Lee, B. S. Chung, D. W. Kim, C. D. Kang, and S. H. Kim
Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1084 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. V. Boddy, J. Sludden, M. J. Griffin, C. Garner, J. Kendrick, P. Mistry, C. Dutreix, D. R. Newell, and S. G. O'Brien
Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia
Clin. Cancer Res., July 15, 2007; 13(14): 4164 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. M. Johnson, B. Saigal, H. Tran, and N. J. Donato
Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects
Clin. Cancer Res., July 15, 2007; 13(14): 4233 - 4244.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dasmahapatra, N. Yerram, Y. Dai, P. Dent, and S. Grant
Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
Clin. Cancer Res., July 15, 2007; 13(14): 4280 - 4290.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Modi, T. McDonald, S. Chu, J.-K. Yee, S. J. Forman, and R. Bhatia
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
Blood, June 15, 2007; 109(12): 5411 - 5421.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. K. Nguyen, M. Rahmani, H. Harada, P. Dent, and S. Grant
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Blood, May 1, 2007; 109(9): 4006 - 4015.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Quintas-Cardama, H. Kantarjian, D. Jones, C. Nicaise, S. O'Brien, F. Giles, M. Talpaz, and J. Cortes
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
Blood, January 15, 2007; 109(2): 497 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al.
Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells.
Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Ferrari-Amorotti, K. Keeshan, M. Zattoni, C. Guerzoni, G. Iotti, S. Cattelani, N. J. Donato, and B. Calabretta
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP{alpha}
Blood, August 15, 2006; 108(4): 1353 - 1362.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al.
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Blood, July 15, 2006; 108(2): 645 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Quintas-Cardama and J. E. Cortes
Chronic Myeloid Leukemia: Diagnosis and Treatment
Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Abruzzese, G. Del Poeta, R. Barbato, S. Fratoni, M. M. Trawinska, D. Zangrilli, A. M. Coletta, I. M. Patroi, F. Francesconi, G. Santeusanio, et al.
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825.
Blood, June 1, 2006; 107(11): 4571 - 4572.
[Full Text] [PDF]

Home page
 BloodHome page
M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford, and T. L. Holyoake
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Blood, June 1, 2006; 107(11): 4532 - 4539.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cortes and H. Kantarjian
New Targeted Approaches in Chronic Myeloid Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6316 - 6324.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia
Blood, May 15, 2005; 105(10): 3995 - 4003.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. R. Burgess, B. J. Skaggs, N. P. Shah, F. Y. Lee, and C. L. Sawyers
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
PNAS, March 1, 2005; 102(9): 3395 - 3400.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. J. Elrick, H. G. Jorgensen, J. C. Mountford, and T. L. Holyoake
Punish the parent not the progeny
Blood, March 1, 2005; 105(5): 1862 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Chu, H. Xu, N. P. Shah, D. S. Snyder, S. J. Forman, C. L. Sawyers, and R. Bhatia
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment
Blood, March 1, 2005; 105(5): 2093 - 2098.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Gumireddy, S. J. Baker, S. C. Cosenza, P. John, A. D. Kang, K. A. Robell, M. V. R. Reddy, and E. P. Reddy
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
PNAS, February 8, 2005; 102(6): 1992 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. O'Hare, R. Pollock, E. P. Stoffregen, J. A. Keats, O. M. Abdullah, E. M. Moseson, V. M. Rivera, H. Tang, C. A. Metcalf III, R. S. Bohacek, et al.
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
Blood, October 15, 2004; 104(8): 2532 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Dai, M. Rahmani, S. J. Corey, P. Dent, and S. Grant
A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2
J. Biol. Chem., August 13, 2004; 279(33): 34227 - 34239.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.